Ortanol (Omeprazole)

Omeprazole, the active ingredient in Ortanol, is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is employed in patients with acid‑related disorders such as GERD, erosive esophagitis, stress‑related mucosal bleeding, and Zollinger‑Ellison syndrome.

GNH USA supplies Ortanol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide.

Ortanol (omeprazole) is used to manage acid‑related disorders by suppressing gastric acid production.

Gastroesophageal reflux disease (GERD): reduces acid exposure to relieve symptoms and promote esophageal healing. Erosive esophagitis: facilitates mucosal recovery by maintaining a higher gastric pH. Prevention of stress‑related mucosal bleeding: lowers gastric acidity to protect the gastric lining in critically ill patients. Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors.

Common and serious adverse reactions have been reported with omeprazole injection.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: transient and usually self‑limiting. - Diarrhea: may occur during the initial days of therapy. - Injection site pain or erythema: localized discomfort at the infusion site.

Serious or Rare Side Effects: - Severe allergic reactions including anaphylaxis. - Clostridioides difficile‑associated diarrhea. - Hepatic enzyme elevation or hepatitis. - Thrombocytopenia or other hematologic abnormalities. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute interstitial nephritis.

When using Ortanol, several safety considerations should be observed. - Assess renal function: dose adjustment may be required in severe renal impairment. - Use with caution in hepatic impairment: monitor liver enzymes regularly. - Monitor for Clostridioides difficile infection: especially during prolonged therapy. - Avoid in patients with known hypersensitivity to omeprazole or other PPIs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: omeprazole reduces its activation, diminishing antiplatelet effect. - Atazanavir and other protease inhibitors: decreased absorption and efficacy. - Ketoconazole and other azole antifungals: reduced bioavailability due to increased gastric pH.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations; monitor levels. - Methotrexate (high‑dose): reduced renal clearance; watch for toxicity. - Theophylline: possible increase in plasma concentrations; adjust dose if needed.